Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies
Ying Yuan(Zhejiang Cancer Hospital), Kefeng Ding(Second Affiliated Hospital of Zhejiang University), Yanhong Deng(Sun Yat-sen University), Xiangjiao Meng(Shandong First Medical University), Zhiye Zhang(Jilin Normal University), Dingzhi Huang(Tianjin Medical University Cancer Institute and Hospital), Zengqing Guo(Fujian Provincial Cancer Hospital), Yi Hu(Union Hospital), Yongdong Jin(Shenzhen University), Huijuan Wang(Sir Run Run Shaw Hospital), Xiaorong Dong(Taiyuan University of Technology), Meili Sun(Jinan Central Hospital), Lian Liu(Qilu Hospital of Shandong University), Dong Hua(Jiangnan University), Mingjun Zhang(Anhui Medical University), Dongde Wu(Hubei Cancer Hospital), Yueyin Pan(University of Science and Technology of China), Xiaoyan Li(Hainan 301 Hospital), Xiuwen Wang(Second Hospital of Shandong University), Zhiwu Wang(Tangshan People's Hospital), Sheng Hu(University of Science and Technology of China), Sujie Zhang(Chinese PLA General Hospital), Mingfang Zhao(First Hospital of China Medical University), Cunji Wang(Hunan Academy of Traditional Chinese Medicine), Jingjing Huang(Innovative Biologics (United States)), Nong Yang(Central South University), Mengna Huang(Brigham and Women's Hospital)
Cited by 14
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456